ПЕУХУ Эмилиа (FI),ХОЛМБОМ Томас (FI),СЬЁХОЛМ Райнер (FI),ЭРИКССОН Джон (FI),ЭКЛУНД Патрик (FI)
申请号：
RU2013127152/15
公开号：
RU2013127152A
申请日:
2011.12.07
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A therapeutic composition comprising a 8-hydroxy- or 8-substituted-dibenzilbutirolaktonovy lignan for use in a method of treating cancer or a similar condition wherein the mammal is broken regulation signal pathway rosta.2 factor. A composition according to claim 1, characterized in that said lignan is selected from the group consisting nortrahelogenin, nortrahelogenina diastereomers, isomers and their nortrahelogenina kombinatsii.3. A composition according to claim 1, characterized in that said lignan is of formula I, wherein each of R, R, r and independently from each other hydrogen, linear or branched C-alkyl or linear or branched Catsil or R independently of one another are carbohydrate residue, iRoboznachaet hydroxyl, alkyl such as linear or branched Ci ^ alkyl or cycloalkyl having from 4 to 8 carbon atoms, acyl, aryl, alkoxy group such as a linear or branched alkoxy group, aryl, having from 1 to 3 aromatic rings, phenoxy Available formula -OAr, where Ar is aryl having from 1 to 3 aromatic rings, possibly substituted, or halogen, in particular bromo, chloro or yod.4. A composition according to any one of claims 1-3, characterized in that said lignan has Formula II, wherein R independently from each other hydrogen, linear or branched Ci ^ alkyl or a linear or branched Catsilnuyu group, particularly, R is hydrogen, or R independently represent a carbohydrate ostatok.5. A composition according to any one of claims 1-3, characterized in that said lignan is selected from 8-metilmatairesinola (8-Me-MAT) and 8-metildimetilmatairesinola (8-Me-dimethyl-MAT) .6. A therapeutic pharmaceutical combination, soda1. Терапевтическая композиция, содержащая 8-гидрокси- или 8-замещенный-дибензилбутиролактоновый лигнан для применения в способе лечения рака или аналогичного состояния, при котором у млекопитающего нарушена регуляция сигнального пути фактора роста.2. Композиция по п.1, отличающаяся тем, что указанный лигнан выбран из группы, включающей нортрахелогенин, диастереомер
